Publication Name	World Journal of Gastroenterology
Manuscript ID	34916
Country	Australia

Received	2017-06-04 13:43
Peer-Review Started	2017-06-06 07:40
To Make the First Decision	2017-06-22 06:00
Return for Revision	2017-06-27 10:37
Revised	2017-07-03 11:58
Second Decision	2017-08-07 05:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-08-15 15:14
Articles in Press	2017-08-15 15:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-09-20 01:03
Publish the Manuscript Online	2017-09-21 07:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
Manuscript Source	Invited Manuscript
All Author List	Abhinav Vasudevan, Peter R Gibson and Daniel R van Langenberg
Funding Agency and Grant Number
Corresponding Author	Abhinav Vasudevan, BM BCh, Doctor, Gastroenterology and Hepatology, Eastern Health and Monash University, Level 2, 5 Arnold Street, Box Hill Hospital, Box Hill 3128, Victoria, Australia. abhinav.vasudevan@gmail.com
Key Words	Crohn’s disease; clinical pharmacology; ulcerative colitis; thiopurines; Inflammatory bowel disease; biologics; nutrition
Core Tip	There appears to be marked variation in time to clinical response for therapies used in inflammatory bowel disease which is further influenced by disease and patient related factors. The most rapid response can be expected with corticosteroids, calcineurin inhibitors, exclusive enteral nutrition, aminosalicylates and anti-tumor necrosis factor therapy (within 2 mo), while methotrexate, thiopurines and vedolizumab can take several months to achieve maximal response. There is a lack of reporting of the time to response of therapies in clinical trials for inflammatory bowel disease and this remains an area that should be addressed in future studies.
Publish Date	2017-09-21 07:51
Citation	Vasudevan A, Gibson PR, van Langenberg DR. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402
URL	http://www.wjgnet.com/1007-9327/full/v23/i35/6385.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i35.6385

Full Article (PDF)	WJG-23-6385.pdf
Full Article (Word)	WJG-23-6385.doc
Manuscript File	34916-Review.docx
Answering Reviewers	34916-Answering reviewers.pdf
Audio Core Tip	34916-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	34916-Conflict-of-interest statement.pdf
Copyright License Agreement	34916-Copyright-Assignment-revision.pdf
Peer-review Report	34916-Peer-review(s).pdf
Scientific Misconduct Check	34916-Scientific misconduct check.pdf
Scientific Editor Work List	34916-Scientific editor work list.pdf